Theratechnologies IPO év
Mi az Theratechnologies IPO év?
A IPO év az Theratechnologies, Inc. - 1996
Mi a IPO év meghatározása?
A kezdeti nyilvános ajánlattétel olyan nyilvános ajánlattétel, amelyben a társaság részvényeit általában olyan intézményi befektetőknek adják el, akik viszont értékpapírcserében először értékesítik a nagyközönségnek.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO év a Health Care szektor a TSX-on cégekben a Theratechnologies -hoz képest
Mit csinál Theratechnologies?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
ipo év -hoz hasonló cégek Theratechnologies
- Shaw Communications nak IPO év 1995 van
- Husky nak IPO év 1995 van
- Transcontinental , Cl B Mv nak IPO év 1995 van
- Mountain Inc nak IPO év 1995 van
- Brookfield Asset Management nak IPO év 1995 van
- ShawCor nak IPO év 1995 van
- Theratechnologies nak IPO év 1996 van
- BXP nak IPO év 1997 van
- Faro Technologies nak IPO év 1997 van
- Silgan nak IPO év 1997 van
- Warrior Gold nak IPO év 1997 van
- Ryanair Plc nak IPO év 1997 van
- SIGA Technologies Inc nak IPO év 1997 van